7月29日电，诺和诺德首席财务官表示，将继续扩大司美格鲁肽（Wegovy）的直接面向消费者销售规模。

Core Viewpoint - Novo Nordisk's CFO announced plans to continue expanding the direct-to-consumer sales of semaglutide (Wegovy) [1] Company Summary - The company is focusing on increasing the availability and accessibility of Wegovy to consumers directly [1] Industry Summary - The direct-to-consumer sales strategy indicates a shift in how pharmaceutical products, particularly weight management drugs, are marketed and sold [1]